FI64357C - Foerfarande foer framstaellning av nya terapeutiskt anvaendbara ftalazin-4-ylaettiksyraderivat - Google Patents
Foerfarande foer framstaellning av nya terapeutiskt anvaendbara ftalazin-4-ylaettiksyraderivat Download PDFInfo
- Publication number
- FI64357C FI64357C FI783844A FI783844A FI64357C FI 64357 C FI64357 C FI 64357C FI 783844 A FI783844 A FI 783844A FI 783844 A FI783844 A FI 783844A FI 64357 C FI64357 C FI 64357C
- Authority
- FI
- Finland
- Prior art keywords
- tai
- jossa
- formula
- tarkoittavat
- dihydro
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 44
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title description 3
- 230000001225 therapeutic effect Effects 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims description 66
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 21
- 239000000460 chlorine Substances 0.000 claims description 20
- 229910052801 chlorine Inorganic materials 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 229910052794 bromium Inorganic materials 0.000 claims description 17
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 15
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical group 0.000 claims description 12
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Chemical group 0.000 claims description 11
- 239000011630 iodine Substances 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 5
- 239000011593 sulfur Chemical group 0.000 claims description 5
- 229910052717 sulfur Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- RIIVBOIBIOLLPO-UHFFFAOYSA-N 2-phthalazin-1-ylacetic acid Chemical class C1=CC=C2C(CC(=O)O)=NN=CC2=C1 RIIVBOIBIOLLPO-UHFFFAOYSA-N 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- XXTZHYXQVWRADW-UHFFFAOYSA-N diazomethanone Chemical compound [N]N=C=O XXTZHYXQVWRADW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 claims 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 4
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 claims 4
- 241001591024 Samea Species 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 241001024099 Olla Species 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 77
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- 239000000203 mixture Substances 0.000 description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 56
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 45
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- -1 hydroxy, benzyloxy Chemical group 0.000 description 40
- 239000007787 solid Substances 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000002253 acid Substances 0.000 description 22
- 239000003208 petroleum Substances 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- 239000007858 starting material Substances 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 238000010992 reflux Methods 0.000 description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 102000016912 Aldehyde Reductase Human genes 0.000 description 14
- 108010053754 Aldehyde reductase Proteins 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- LKBFFDOJUKLQNY-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxo-1-phthalazinyl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1F LKBFFDOJUKLQNY-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000600 sorbitol Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 125000004494 ethyl ester group Chemical group 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000004702 methyl esters Chemical class 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YZIFVWOCPGPNHB-UHFFFAOYSA-N 1,2-dichloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C(Cl)=C1 YZIFVWOCPGPNHB-UHFFFAOYSA-N 0.000 description 4
- ADJFSVNVKXPIAX-UHFFFAOYSA-N 2-[3-[(4-bromo-3-chlorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C(Cl)=C1 ADJFSVNVKXPIAX-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- 150000004703 alkoxides Chemical class 0.000 description 4
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical class CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 235000011181 potassium carbonates Nutrition 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000005846 sugar alcohols Chemical class 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- YVVJWIIUPHLVBK-UHFFFAOYSA-N (4-bromo-2-fluorophenyl)methylhydrazine Chemical class NNCC1=CC=C(Br)C=C1F YVVJWIIUPHLVBK-UHFFFAOYSA-N 0.000 description 3
- ZEDQLIHBPGNGEC-UHFFFAOYSA-N 2-(4-oxo-3h-phthalazin-1-yl)acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=NNC(=O)C2=C1 ZEDQLIHBPGNGEC-UHFFFAOYSA-N 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 3
- XMHNLZXYPAULDF-UHFFFAOYSA-N 4-bromo-1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC(Br)=CC=C1CBr XMHNLZXYPAULDF-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000027472 Galactosemias Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000007239 Wittig reaction Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000003497 sciatic nerve Anatomy 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- ZFDJCFRZDCALEA-UHFFFAOYSA-N 2-[3-[(2-fluoro-4-iodophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(I)C=C1F ZFDJCFRZDCALEA-UHFFFAOYSA-N 0.000 description 2
- NVYHDIAYWZUMKV-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-sulfanylidenephthalazin-1-yl]acetic acid Chemical compound S=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1F NVYHDIAYWZUMKV-UHFFFAOYSA-N 0.000 description 2
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 2
- 125000006512 3,4-dichlorobenzyl group Chemical group [H]C1=C(Cl)C(Cl)=C([H])C(=C1[H])C([H])([H])* 0.000 description 2
- LUJPVUREAUEIJM-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-6-methoxy-4-oxophthalazine-1-carboxylic acid Chemical compound O=C1C2=CC(OC)=CC=C2C(C(O)=O)=NN1CC1=CC=C(Cl)C(Cl)=C1 LUJPVUREAUEIJM-UHFFFAOYSA-N 0.000 description 2
- SEVNPZGAQGOAKQ-UHFFFAOYSA-N 3-[(4-bromo-2-fluorophenyl)methyl]-7-fluoro-4-oxophthalazine-1-carboxylic acid Chemical compound O=C1C2=CC=C(F)C=C2C(C(=O)O)=NN1CC1=CC=C(Br)C=C1F SEVNPZGAQGOAKQ-UHFFFAOYSA-N 0.000 description 2
- BMOXAGGNAVGFIQ-UHFFFAOYSA-N 6,7-dichloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazine-1-carboxylic acid Chemical compound O=C1C2=CC(Cl)=C(Cl)C=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 BMOXAGGNAVGFIQ-UHFFFAOYSA-N 0.000 description 2
- CQEWXWUAKKWJEK-UHFFFAOYSA-N 6-chloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazine-1-carboxylic acid Chemical compound O=C1C2=CC(Cl)=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 CQEWXWUAKKWJEK-UHFFFAOYSA-N 0.000 description 2
- DEUBEPSCLJDLKR-UHFFFAOYSA-N 6-methoxy-4-oxo-3h-phthalazine-1-carboxylic acid Chemical compound OC(=O)C1=NNC(=O)C2=CC(OC)=CC=C21 DEUBEPSCLJDLKR-UHFFFAOYSA-N 0.000 description 2
- LEYPGYBULHCFFU-UHFFFAOYSA-N 7-chloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazine-1-carboxylic acid Chemical compound O=C1C2=CC=C(Cl)C=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 LEYPGYBULHCFFU-UHFFFAOYSA-N 0.000 description 2
- JRLTTZUODKEYDH-UHFFFAOYSA-N 8-methylquinoline Chemical group C1=CN=C2C(C)=CC=CC2=C1 JRLTTZUODKEYDH-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HXTWSRHHRRWRDG-UHFFFAOYSA-L [K+].[K+].[S-]SSS[S-] Chemical compound [K+].[K+].[S-]SSS[S-] HXTWSRHHRRWRDG-UHFFFAOYSA-L 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 125000005530 alkylenedioxy group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical class C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical compound C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 2
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XKMGDVJBAWUUDZ-YVMONPNESA-N (2z)-2-(3-oxo-2-benzofuran-1-ylidene)acetic acid Chemical compound C1=CC=C2C(=C/C(=O)O)/OC(=O)C2=C1 XKMGDVJBAWUUDZ-YVMONPNESA-N 0.000 description 1
- OMBMILBFFMGAJD-UHFFFAOYSA-N (3,4-dichlorophenyl)methylhydrazine Chemical compound NNCC1=CC=C(Cl)C(Cl)=C1 OMBMILBFFMGAJD-UHFFFAOYSA-N 0.000 description 1
- KWZJFFIYJILLRX-UHFFFAOYSA-N (4-bromo-3-chlorophenyl)methylhydrazine Chemical compound NNCC1=CC=C(Br)C(Cl)=C1 KWZJFFIYJILLRX-UHFFFAOYSA-N 0.000 description 1
- YLOBWCNYVJFZMF-UHFFFAOYSA-N (4-oxo-3h-phthalazin-1-yl) acetate Chemical class C1=CC=C2C(OC(=O)C)=NNC(=O)C2=C1 YLOBWCNYVJFZMF-UHFFFAOYSA-N 0.000 description 1
- SGUZXTCPCSYLNY-UHFFFAOYSA-N 1-(4-chloro-2-methylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1C SGUZXTCPCSYLNY-UHFFFAOYSA-N 0.000 description 1
- XCJXYTFYKPVYMK-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC(CBr)=CC=C1Br XCJXYTFYKPVYMK-UHFFFAOYSA-N 0.000 description 1
- YLRBJYMANQKEAW-UHFFFAOYSA-N 1-bromo-4-(bromomethyl)benzene Chemical compound BrCC1=CC=C(Br)C=C1 YLRBJYMANQKEAW-UHFFFAOYSA-N 0.000 description 1
- RQPPZGICNYEPHM-UHFFFAOYSA-N 2-(3-benzyl-4-oxophthalazin-1-yl)acetic acid Chemical class O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=CC=C1 RQPPZGICNYEPHM-UHFFFAOYSA-N 0.000 description 1
- XCQDCQKNZXMXGM-UHFFFAOYSA-N 2-(4-chlorophenyl)-4,4-dimethyl-5h-1,3-oxazole Chemical compound CC1(C)COC(C=2C=CC(Cl)=CC=2)=N1 XCQDCQKNZXMXGM-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- PHGLYQGVAGLHTN-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetic acid Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)O)C1=CC=CC=C1 PHGLYQGVAGLHTN-UHFFFAOYSA-N 0.000 description 1
- SBCDVLQYIOATAH-UHFFFAOYSA-N 2-[3-[(3,4-dichlorophenyl)methyl]-6-fluoro-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC(F)=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 SBCDVLQYIOATAH-UHFFFAOYSA-N 0.000 description 1
- UZOBGENOTABUTH-UHFFFAOYSA-N 2-[3-[(3,4-dichlorophenyl)methyl]-6-methoxy-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC(OC)=CC=C2C(CC(O)=O)=NN1CC1=CC=C(Cl)C(Cl)=C1 UZOBGENOTABUTH-UHFFFAOYSA-N 0.000 description 1
- OYPHTIYQNAUXBW-UHFFFAOYSA-N 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxophthalazin-1-yl]acetyl chloride Chemical compound FC1=CC(Br)=CC=C1CN1C(=O)C2=CC=CC=C2C(CC(Cl)=O)=N1 OYPHTIYQNAUXBW-UHFFFAOYSA-N 0.000 description 1
- LRAXKCLGYVGGHD-UHFFFAOYSA-N 2-[3-[(4-bromophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Br)C=C1 LRAXKCLGYVGGHD-UHFFFAOYSA-N 0.000 description 1
- OVUCIWDGRHFERU-UHFFFAOYSA-N 2-[3-[(4-chloro-2-fluorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Cl)C=C1F OVUCIWDGRHFERU-UHFFFAOYSA-N 0.000 description 1
- SBMYBOVJMOVVQW-UHFFFAOYSA-N 2-[3-[[4-(2,2-difluoroethyl)piperazin-1-yl]methyl]-4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound FC(CN1CCN(CC1)CC1=NN(C=C1C=1C=NC(=NC=1)NC1CC2=CC=CC=C2C1)CC(=O)N1CC2=C(CC1)NN=N2)F SBMYBOVJMOVVQW-UHFFFAOYSA-N 0.000 description 1
- LPZFWDTVRPHQPU-UHFFFAOYSA-N 2-[4-oxo-3-(2-pyridin-2-ylethyl)phthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=CC=C2C(CC(=O)O)=NN1CCC1=CC=CC=N1 LPZFWDTVRPHQPU-UHFFFAOYSA-N 0.000 description 1
- KCICYQVJHHWPIU-UHFFFAOYSA-N 2-[6,7-dichloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC(Cl)=C(Cl)C=C2C(CC(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 KCICYQVJHHWPIU-UHFFFAOYSA-N 0.000 description 1
- VNIUZGHAYQBEGJ-UHFFFAOYSA-N 2-[6-chloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC(Cl)=CC=C2C(CC(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 VNIUZGHAYQBEGJ-UHFFFAOYSA-N 0.000 description 1
- FVGWEOULJRHOHU-UHFFFAOYSA-N 2-[7-chloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazin-1-yl]acetic acid Chemical compound O=C1C2=CC=C(Cl)C=C2C(CC(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 FVGWEOULJRHOHU-UHFFFAOYSA-N 0.000 description 1
- WQSKRNLQCOTUDF-UHFFFAOYSA-N 2-acetyl-7-methoxyphthalazin-1-one Chemical compound C(C)(=O)N1C(C2=CC(=CC=C2C=N1)OC)=O WQSKRNLQCOTUDF-UHFFFAOYSA-N 0.000 description 1
- ZXTHWIZHGLNEPG-UHFFFAOYSA-N 2-phenyl-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=CC=CC=C1 ZXTHWIZHGLNEPG-UHFFFAOYSA-N 0.000 description 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
- FESBKRXLRCAGLD-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-6-fluoro-4-oxophthalazine-1-carboxylic acid Chemical compound O=C1C2=CC(F)=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C(Cl)=C1 FESBKRXLRCAGLD-UHFFFAOYSA-N 0.000 description 1
- HDEPYJUDJCBEGX-UHFFFAOYSA-N 3-[(3,4-dichlorophenyl)methyl]-6-methoxy-4-oxophthalazine-1-carbonyl chloride Chemical compound O=C1C2=CC(OC)=CC=C2C(C(Cl)=O)=NN1CC1=CC=C(Cl)C(Cl)=C1 HDEPYJUDJCBEGX-UHFFFAOYSA-N 0.000 description 1
- MWUOJNPUNIJKFH-UHFFFAOYSA-N 4-N-methyl-4-N-nitrosobenzene-1,4-dicarboxamide Chemical compound C(C1=CC=C(C(=O)N)C=C1)(=O)N(C)N=O MWUOJNPUNIJKFH-UHFFFAOYSA-N 0.000 description 1
- 125000006281 4-bromobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)C([H])([H])* 0.000 description 1
- WWJAZKZLSDRAIV-UHFFFAOYSA-N 4-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=CC2=C1C(=O)OC2=O WWJAZKZLSDRAIV-UHFFFAOYSA-N 0.000 description 1
- TWWAWPHAOPTQEU-UHFFFAOYSA-N 4-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)OC2=O TWWAWPHAOPTQEU-UHFFFAOYSA-N 0.000 description 1
- ZOXBWJMCXHTKNU-UHFFFAOYSA-N 5-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=C2C(=O)OC(=O)C2=C1 ZOXBWJMCXHTKNU-UHFFFAOYSA-N 0.000 description 1
- DJTTYKYPOPUMSB-UHFFFAOYSA-N 6,7-dichloro-4-oxo-3h-phthalazine-1-carboxylic acid Chemical compound ClC1=C(Cl)C=C2C(C(=O)O)=NNC(=O)C2=C1 DJTTYKYPOPUMSB-UHFFFAOYSA-N 0.000 description 1
- UGOUQRFEVLPUPL-UHFFFAOYSA-N 6-chloro-2-methylphthalazin-1-one Chemical compound ClC1=CC=C2C(=O)N(C)N=CC2=C1 UGOUQRFEVLPUPL-UHFFFAOYSA-N 0.000 description 1
- CJLKDNJCPXSCOP-UHFFFAOYSA-N 6-chloro-4-oxo-3h-phthalazine-1-carboxylic acid Chemical compound ClC1=CC=C2C(C(=O)O)=NNC(=O)C2=C1 CJLKDNJCPXSCOP-UHFFFAOYSA-N 0.000 description 1
- VRZIBODNPOALGX-UHFFFAOYSA-N 7-chloro-4-oxo-3h-phthalazine-1-carboxylic acid Chemical compound C1=C(Cl)C=C2C(C(=O)O)=NNC(=O)C2=C1 VRZIBODNPOALGX-UHFFFAOYSA-N 0.000 description 1
- ZYKVRFMMRAPHAZ-UHFFFAOYSA-N 7-fluoro-3 Chemical compound C1S(=O)(=O)CC(C=2)=CC(F)=CC=2CS(=O)(=O)CC2=CC=C1C=C2 ZYKVRFMMRAPHAZ-UHFFFAOYSA-N 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VQIGHJRTOMYFST-UHFFFAOYSA-N C(C)(=O)OC1=NN(C(C2=CC(=CC=C12)C)=O)CC1=CC(=C(C=C1)Cl)Cl Chemical compound C(C)(=O)OC1=NN(C(C2=CC(=CC=C12)C)=O)CC1=CC(=C(C=C1)Cl)Cl VQIGHJRTOMYFST-UHFFFAOYSA-N 0.000 description 1
- XFBQEVDJQBGJRB-UHFFFAOYSA-N C(C)(=O)OC1=NN(C(C2=CC=CC=C12)=O)CC1=CC(=C(C=C1)Br)Cl.C(CC)O Chemical compound C(C)(=O)OC1=NN(C(C2=CC=CC=C12)=O)CC1=CC(=C(C=C1)Br)Cl.C(CC)O XFBQEVDJQBGJRB-UHFFFAOYSA-N 0.000 description 1
- AUOWQCJQNLILGW-UHFFFAOYSA-N C(C)C1=NN(C(C2=C(C=CC=C12)C)=O)CC1=CC(=C(C=C1)Cl)Cl Chemical compound C(C)C1=NN(C(C2=C(C=CC=C12)C)=O)CC1=CC(=C(C=C1)Cl)Cl AUOWQCJQNLILGW-UHFFFAOYSA-N 0.000 description 1
- FTEPNRLEKNQXIQ-UHFFFAOYSA-N COC1=CC=C2C(=NNOC2=C1)C(=O)OC Chemical compound COC1=CC=C2C(=NNOC2=C1)C(=O)OC FTEPNRLEKNQXIQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- VLBOLSUVAQVTDM-UHFFFAOYSA-N FC1=C(CN2C(C3=CC=CC=C3C=N2)=O)C=CC(=C1)Br.[Na] Chemical compound FC1=C(CN2C(C3=CC=CC=C3C=N2)=O)C=CC(=C1)Br.[Na] VLBOLSUVAQVTDM-UHFFFAOYSA-N 0.000 description 1
- VNCDFBOPQPZYPV-UHFFFAOYSA-N FC1=C(CN2OC3=CC=C(C=C3C(=N2)C(=O)OC)F)C=CC(=C1)Br Chemical compound FC1=C(CN2OC3=CC=C(C=C3C(=N2)C(=O)OC)F)C=CC(=C1)Br VNCDFBOPQPZYPV-UHFFFAOYSA-N 0.000 description 1
- KBIFYKYALGVFQG-UHFFFAOYSA-N FC1=CC=C2C(=NNC(C2=C1)=O)C(=O)O.ClC=1C=C(CN2C(C3=CC(=CC=C3C(=N2)C(=O)O)F)=O)C=CC1Cl Chemical compound FC1=CC=C2C(=NNC(C2=C1)=O)C(=O)O.ClC=1C=C(CN2C(C3=CC(=CC=C3C(=N2)C(=O)O)F)=O)C=CC1Cl KBIFYKYALGVFQG-UHFFFAOYSA-N 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000001344 Macular Edema Diseases 0.000 description 1
- 206010025415 Macular oedema Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- MODGUXHMLLXODK-UHFFFAOYSA-N [Br].CO Chemical compound [Br].CO MODGUXHMLLXODK-UHFFFAOYSA-N 0.000 description 1
- WBLXMRIMSGHSAC-UHFFFAOYSA-N [Cl].[Cl] Chemical compound [Cl].[Cl] WBLXMRIMSGHSAC-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 150000001243 acetic acids Chemical class 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000003288 aldose reductase inhibitor Substances 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- CQZZTFWSVOOPJL-UHFFFAOYSA-N ethyl 2-[3-[(4-bromo-2-fluorophenyl)methyl]-4-oxophthalazin-1-yl]acetate Chemical compound O=C1C2=CC=CC=C2C(CC(=O)OCC)=NN1CC1=CC=C(Br)C=C1F CQZZTFWSVOOPJL-UHFFFAOYSA-N 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- FQMQTNHJHYXQLK-UHFFFAOYSA-N furo[3,4-f][1,3]benzodioxole-5,7-dione Chemical compound C1=C2C(=O)OC(=O)C2=CC2=C1OCO2 FQMQTNHJHYXQLK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003350 kerosene Substances 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000010230 macular retinal edema Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical compound [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- DNERGKSACZVPHJ-UHFFFAOYSA-N methyl 6,7-dichloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazine-1-carboxylate Chemical compound O=C1C2=CC(Cl)=C(Cl)C=C2C(C(=O)OC)=NN1CC1=CC=C(Cl)C(Cl)=C1 DNERGKSACZVPHJ-UHFFFAOYSA-N 0.000 description 1
- IPCSECDGZMAIKO-UHFFFAOYSA-N methyl 6-chloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazine-1-carboxylate Chemical compound O=C1C2=CC(Cl)=CC=C2C(C(=O)OC)=NN1CC1=CC=C(Cl)C(Cl)=C1 IPCSECDGZMAIKO-UHFFFAOYSA-N 0.000 description 1
- XNTUUMINCPQMPE-UHFFFAOYSA-N methyl 6-chloro-4-oxo-3h-phthalazine-1-carboxylate Chemical compound ClC1=CC=C2C(C(=O)OC)=NNC(=O)C2=C1 XNTUUMINCPQMPE-UHFFFAOYSA-N 0.000 description 1
- GEJOQBHXXSAWEQ-UHFFFAOYSA-N methyl 7-chloro-3-[(3,4-dichlorophenyl)methyl]-4-oxophthalazine-1-carboxylate Chemical compound O=C1C2=CC=C(Cl)C=C2C(C(=O)OC)=NN1CC1=CC=C(Cl)C(Cl)=C1 GEJOQBHXXSAWEQ-UHFFFAOYSA-N 0.000 description 1
- YHAZUQHMKGNKHG-UHFFFAOYSA-N methyl 7-fluoro-4-oxo-3h-phthalazine-1-carboxylate Chemical compound C1=C(F)C=C2C(C(=O)OC)=NNC(=O)C2=C1 YHAZUQHMKGNKHG-UHFFFAOYSA-N 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 150000003901 oxalic acid esters Chemical class 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical compound C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 description 1
- MLGFHJHBQIXXDW-UHFFFAOYSA-N phthalazine-1-carboxylic acid Chemical class C1=CC=C2C(C(=O)O)=NN=CC2=C1 MLGFHJHBQIXXDW-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- FZJCXIDLUFPGPP-UHFFFAOYSA-N propan-2-ol;toluene Chemical compound CC(C)O.CC1=CC=CC=C1 FZJCXIDLUFPGPP-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MHSKRLJMQQNJNC-UHFFFAOYSA-N terephthalamide Chemical compound NC(=O)C1=CC=C(C(N)=O)C=C1 MHSKRLJMQQNJNC-UHFFFAOYSA-N 0.000 description 1
- NWUWMQRSDSSETA-UHFFFAOYSA-N thallane Chemical compound [TlH3] NWUWMQRSDSSETA-UHFFFAOYSA-N 0.000 description 1
- 229910000089 thallane Inorganic materials 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- IIHPVYJPDKJYOU-UHFFFAOYSA-N triphenylcarbethoxymethylenephosphorane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)OCC)C1=CC=CC=C1 IIHPVYJPDKJYOU-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5414277 | 1977-12-29 | ||
| GB5414277 | 1977-12-29 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI783844A7 FI783844A7 (fi) | 1979-06-30 |
| FI64357B FI64357B (fi) | 1983-07-29 |
| FI64357C true FI64357C (fi) | 1983-11-10 |
Family
ID=10470067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI783844A FI64357C (fi) | 1977-12-29 | 1978-12-14 | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara ftalazin-4-ylaettiksyraderivat |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US4251528A (en, 2012) |
| EP (1) | EP0002895B1 (en, 2012) |
| JP (2) | JPS5495582A (en, 2012) |
| AT (1) | AT365581B (en, 2012) |
| AU (1) | AU516264B2 (en, 2012) |
| BG (1) | BG34336A3 (en, 2012) |
| CA (1) | CA1107732A (en, 2012) |
| CS (1) | CS241015B2 (en, 2012) |
| CY (1) | CY1219A (en, 2012) |
| DD (1) | DD141021A5 (en, 2012) |
| DE (1) | DE2861170D1 (en, 2012) |
| DK (1) | DK151253C (en, 2012) |
| ES (1) | ES476496A1 (en, 2012) |
| FI (1) | FI64357C (en, 2012) |
| GR (1) | GR65303B (en, 2012) |
| HK (1) | HK22484A (en, 2012) |
| HU (1) | HU182585B (en, 2012) |
| IE (1) | IE47592B1 (en, 2012) |
| IL (1) | IL56099A0 (en, 2012) |
| IN (1) | IN150196B (en, 2012) |
| IT (1) | IT1110885B (en, 2012) |
| MY (1) | MY8500359A (en, 2012) |
| NO (1) | NO154346C (en, 2012) |
| NZ (1) | NZ189034A (en, 2012) |
| PH (1) | PH15435A (en, 2012) |
| PL (1) | PL118443B1 (en, 2012) |
| PT (1) | PT68956A (en, 2012) |
| SG (1) | SG68683G (en, 2012) |
| SU (3) | SU1087075A3 (en, 2012) |
| YU (3) | YU41607B (en, 2012) |
| ZW (1) | ZW24978A1 (en, 2012) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| CA1143733A (en) * | 1979-07-31 | 1983-03-29 | Masao Yoshida | Producing 7-alkoxycarbonyl-6,8-dimethyl-4- hydroxymethyl-1-phthalazone and intermediates |
| US4762839A (en) * | 1985-06-06 | 1988-08-09 | Tanabe Seiyaku Co., Ltd. | Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications |
| EP0222576B1 (en) * | 1985-11-07 | 1992-03-18 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| JPS63132889A (ja) * | 1986-11-21 | 1988-06-04 | Tanabe Seiyaku Co Ltd | キナゾリノン誘導体 |
| WO1993013092A1 (en) * | 1986-11-24 | 1993-07-08 | Reinhard Sarges | Imidazolidinedione derivatives |
| GB8704569D0 (en) * | 1987-02-26 | 1987-04-01 | Ici America Inc | Therapeutic agent |
| US4868301A (en) * | 1987-06-09 | 1989-09-19 | Pfizer Inc. | Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains |
| JPH0676391B2 (ja) * | 1987-06-09 | 1994-09-28 | フアイザー・インコーポレイテツド | ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法 |
| DK607188A (da) * | 1987-11-02 | 1989-06-22 | Merck & Co Inc | Tablet indeholdende en phthalazineddikesyreforbindelse |
| NZ226696A (en) * | 1987-11-02 | 1991-10-25 | Merck & Co Inc | Tablet composition comprising a phthalazine acetic acid derivative as the active ingredient present in from 83-88 wt% |
| US4880928A (en) * | 1987-12-21 | 1989-11-14 | Merck & Co., Inc. | Process for the preparation of 3-((4-bromo-2-fluorophenyl)methyl)-3,4-dihydro-4-oxo-1-phthalazine-acetic acid |
| US4904782A (en) * | 1988-02-29 | 1990-02-27 | Pfizer Inc. | Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate |
| US4940791A (en) * | 1988-02-29 | 1990-07-10 | Pfizer Inc. | Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate |
| US4996204A (en) * | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| US4954629A (en) * | 1989-05-11 | 1990-09-04 | Pfizer Inc. | Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof |
| EP0397930A1 (en) * | 1989-05-18 | 1990-11-22 | Merck & Co. Inc. | Process for the preparation of 3-[(4-bromo-2-fluorophenyl) methyl]-3,4-dihydro-4-oxo-1-phthalazineacetic acid |
| FR2647676A1 (fr) * | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| FI922308A7 (fi) * | 1989-12-15 | 1992-05-21 | Pfizer | Substituoituja oksoftalatsinyylietikkahappoja ja niiden anologeja |
| US5037831A (en) * | 1990-05-21 | 1991-08-06 | American Home Products Corporation | Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors |
| FR2682108B1 (fr) * | 1991-10-07 | 1994-01-07 | Lipha | Acide 3,4-dihydro-4-oxo-3(prop-2-enyl)-1-phtalazineacetiques et derives, leurs preparations et medicaments les contenant. |
| KR950703539A (ko) * | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
| WO1994010151A1 (en) * | 1992-11-02 | 1994-05-11 | Merck & Co., Inc. | Substituted phthalazinones as nerotensin antagonists |
| CH683965A5 (it) * | 1993-02-19 | 1994-06-30 | Limad Marketing Exp & Imp | Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici. |
| AU7195594A (en) * | 1993-07-26 | 1995-02-20 | Fujisawa Pharmaceutical Co., Ltd. | Oxophthalazines for treating cachexia |
| AU6473898A (en) * | 1997-03-21 | 1998-10-20 | Regents Of The University Of California, The | Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors |
| US6696407B1 (en) | 1997-03-21 | 2004-02-24 | The Regents Of The University Of California | Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF |
| NZ516696A (en) * | 1997-04-15 | 2003-08-29 | Csir | Pharmaceutical compositions having appetite suppressant activity |
| SK7522001A3 (en) | 1998-03-31 | 2002-02-05 | Inst For Pharm Discovery Inc | Substituted indolealkanoic acids |
| TNSN99224A1 (fr) * | 1998-12-01 | 2005-11-10 | Inst For Pharm Discovery Inc | Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique |
| GB2396815B (en) * | 1999-10-27 | 2004-09-08 | Phytopharm Plc | A composition comprising a pregnenone derivative and an NSAID |
| DE19963607B4 (de) * | 1999-12-23 | 2005-12-15 | Schering Ag | Verfahren zur Herstellung von 4-(Heteroaryl-methyl) halogen-1(2H)-phthalazinonen |
| GB2363985B (en) | 2000-06-30 | 2004-09-29 | Phytopharm Plc | Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use |
| EP1337272A2 (en) * | 2000-11-30 | 2003-08-27 | Pfizer Products Inc. | Combination of gaba agonists and aldose reductase inhibitors |
| DE60204611T2 (de) | 2001-02-28 | 2006-05-11 | Pfizer Products Inc., Groton | Sulfonyl-pyridazinon-derivate zur Verwendung als Aldose-reduktase-inhibitoren |
| KR100586138B1 (ko) * | 2001-03-30 | 2006-06-07 | 화이자 프로덕츠 인코포레이티드 | 피리다지논 알도스 리덕타제 저해제 |
| CN1505514A (zh) * | 2001-04-30 | 2004-06-16 | �Ʒ� | 醛糖还原酶抑制剂与环加氧酶-2抑制剂的组合 |
| AU761191B2 (en) | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| US20050209237A1 (en) * | 2002-04-30 | 2005-09-22 | Brazzell Romulus K | Method for decreasing capillary permeability in the retina |
| EP1539175A4 (en) * | 2002-07-26 | 2007-09-26 | Inst For Pharm Discovery Inc | SUBSTITUTED INDOLALCANIC ACID DERIVATIVES AND FORMULATIONS CONTAINING THEREOF FOR USE IN THE TREATMENT OF DIABETIC COMPLICATIONS |
| US7572910B2 (en) * | 2003-02-20 | 2009-08-11 | Pfizer, Inc. | Pyridazinone aldose reductase inhibitors |
| US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
| JP4838582B2 (ja) * | 2004-12-27 | 2011-12-14 | 岐阜プラスチック工業株式会社 | 台車用本体 |
| JP2010520913A (ja) | 2007-03-12 | 2010-06-17 | サズセ アーペーエス | ルイボスの抗糖尿病性抽出物 |
| WO2008118844A1 (en) | 2007-03-23 | 2008-10-02 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibitors |
| US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
| JP5976010B2 (ja) | 2010-12-23 | 2016-08-23 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Ｃｏｐｄを処置する方法 |
| MX372739B (es) | 2012-12-14 | 2020-05-06 | Phusis Therapeutics Inc | Metodos y composiciones para inhibir cnksr1. |
| US10227356B2 (en) | 2015-04-20 | 2019-03-12 | Phusis Therapeutics, Inc. | Compounds, compositions and methods for inhibiting CNKSR1 |
| US12090142B2 (en) | 2018-02-22 | 2024-09-17 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of cancer |
| KR102857329B1 (ko) * | 2018-10-04 | 2025-09-10 | 닛토덴코 가부시키가이샤 | 내열 이형 시트 및 열 압착 방법 |
| JP6751974B1 (ja) * | 2019-10-16 | 2020-09-09 | 株式会社コバヤシ | 離型フィルム及び離型フィルムの製造方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833579A (en) * | 1935-11-11 | 1974-09-03 | Inoue Michiro | 4-carbamoyl phthalazones |
| JPS5116430B2 (en, 2012) * | 1971-08-05 | 1976-05-24 | ||
| GB1398549A (en) * | 1972-11-06 | 1975-06-25 | Boots Co Ltd | Phthalazine derivatives and their use in pharmaceutical compo sitions |
| AR205004A1 (es) * | 1973-10-30 | 1976-03-31 | Ishikawa M | Procedimiento para preparar derivados de 6,8-dialquil-7-alcoxi-carbonil-4-hidroximetil-1-ftalazona y la 7,8-lactona |
| DE2451117A1 (de) * | 1973-10-31 | 1975-05-22 | Boots Co Ltd | Therapeutisch wirksame verbindungen |
| IE43079B1 (en) * | 1975-03-20 | 1980-12-17 | Ici Ltd | Quinolone derivatives |
| GB1502312A (en) | 1975-03-20 | 1978-03-01 | Ici Ltd | Quinolone derivatives |
| JPS5214788A (en) * | 1975-07-21 | 1977-02-03 | Fuji Photo Film Co Ltd | Process for preparing phthalazinone and its derivatives |
| NL7702763A (nl) * | 1976-03-18 | 1977-09-20 | Takio Shimamoto En Masayuki Is | Werkwijze voor de bereiding van thromboxaan- -antagonisten en van preparaten die deze stof- fen bevatten. |
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4293553A (en) * | 1978-08-11 | 1981-10-06 | Masayuki Ishikawa | 1-Phthalazone derivatives, and use thereof |
-
1978
- 1978-11-27 IE IE2337/78A patent/IE47592B1/en not_active IP Right Cessation
- 1978-11-28 IN IN860/DEL/78A patent/IN150196B/en unknown
- 1978-11-28 NZ NZ189034A patent/NZ189034A/xx unknown
- 1978-11-29 US US05/964,725 patent/US4251528A/en not_active Expired - Lifetime
- 1978-11-29 AU AU42040/78A patent/AU516264B2/en not_active Expired
- 1978-11-30 IL IL56099A patent/IL56099A0/xx not_active IP Right Cessation
- 1978-11-30 DK DK541878A patent/DK151253C/da not_active IP Right Cessation
- 1978-12-01 EP EP78300720A patent/EP0002895B1/en not_active Expired
- 1978-12-01 DE DE7878300720T patent/DE2861170D1/de not_active Expired
- 1978-12-01 CY CY1219A patent/CY1219A/xx unknown
- 1978-12-06 PH PH21901A patent/PH15435A/en unknown
- 1978-12-12 GR GR57849A patent/GR65303B/el unknown
- 1978-12-14 FI FI783844A patent/FI64357C/fi not_active IP Right Cessation
- 1978-12-16 PL PL1978222157A patent/PL118443B1/pl unknown
- 1978-12-20 PT PT68956A patent/PT68956A/pt not_active IP Right Cessation
- 1978-12-20 SU SU782698853A patent/SU1087075A3/ru active
- 1978-12-21 JP JP15695378A patent/JPS5495582A/ja active Granted
- 1978-12-21 CA CA318,345A patent/CA1107732A/en not_active Expired
- 1978-12-22 HU HU78IE856A patent/HU182585B/hu not_active IP Right Cessation
- 1978-12-26 BG BG041857A patent/BG34336A3/xx unknown
- 1978-12-28 IT IT52480/78A patent/IT1110885B/it active
- 1978-12-28 ZW ZW249/78A patent/ZW24978A1/xx unknown
- 1978-12-28 NO NO784397A patent/NO154346C/no unknown
- 1978-12-28 CS CS789084A patent/CS241015B2/cs unknown
- 1978-12-29 DD DD78210284A patent/DD141021A5/de not_active IP Right Cessation
- 1978-12-29 AT AT0937678A patent/AT365581B/de not_active IP Right Cessation
- 1978-12-29 ES ES476496A patent/ES476496A1/es not_active Expired
- 1978-12-29 YU YU3127/78A patent/YU41607B/xx unknown
-
1980
- 1980-10-06 US US06/194,211 patent/US4393062A/en not_active Expired - Lifetime
-
1981
- 1981-12-04 SU SU813359636A patent/SU1072803A3/ru active
- 1981-12-04 SU SU813359216A patent/SU1272984A3/ru active
-
1982
- 1982-10-14 YU YU2320/82A patent/YU42054B/xx unknown
- 1982-10-14 YU YU2321/82A patent/YU42807B/xx unknown
-
1983
- 1983-11-11 SG SG68683A patent/SG68683G/en unknown
-
1984
- 1984-03-15 HK HK224/84A patent/HK22484A/en unknown
-
1985
- 1985-12-30 MY MY359/85A patent/MY8500359A/xx unknown
-
1987
- 1987-10-28 JP JP62270508A patent/JPS63119469A/ja active Granted
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI64357C (fi) | Foerfarande foer framstaellning av nya terapeutiskt anvaendbara ftalazin-4-ylaettiksyraderivat | |
| US4110337A (en) | Triazolobenzodiazepines | |
| EP0065392B1 (en) | Pharmaceutical compositions containing spiro succinimide derivatives | |
| US3951999A (en) | Anti-inflammatory 1,2-benzisoxazole derivatives | |
| IL45585A (en) | 6,11-dihydrodibenz(b,e)oxepin-acetic acids and derivative | |
| FR2647676A1 (fr) | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase | |
| IE49541B1 (en) | 4,5-dihydro-1-(3-mercapto-1-oxopropyl)-3-phenyl-1h-pyrazole-5-carboxylic acid and derivatives thereof | |
| KR920000956B1 (ko) | 아줄렌 유도체의 제조방법 | |
| US4390541A (en) | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease | |
| US4053600A (en) | Tricyclic 1,2,4-triazolo-quinazolines | |
| NO160133B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2-amino-3-(halobenzoyl)-methylfenyleddiksyrer, estere og salter derav. | |
| WO1990001481A1 (en) | Therapeutic agents | |
| US3450698A (en) | Phenthiazine derivatives | |
| US4226860A (en) | Spiroindolones | |
| JPS6031823B2 (ja) | カルバゾ−ル誘導体の製造方法 | |
| HU194254B (en) | Process for producing new thieno-1,2-thiazol derivatives | |
| KR820001929B1 (ko) | 프탈라진-4-일아세트산의 제조방법 | |
| KR820001931B1 (ko) | 프탈라진-4-일 아세트산 유도체의 제조방법 | |
| US3835152A (en) | 3-cyano-9-benzoyl-1,2,3,4-tetrahydro carbazole | |
| CA1042006A (en) | Isoxazole derivatives | |
| JPS5924992B2 (ja) | ピリド〔２，３−ｄ〕ピリミジン誘導体およびその製法 | |
| JPH02108684A (ja) | ベンゾピラン誘導体の製造法 | |
| PL118444B1 (en) | Process for preparing novel derivatives of phtalazinyl-4-acetic acidh-uksusnojj kisloty | |
| HU208975B (en) | Process for producing imidazo/5,1-b/ quinazolin-9-one derivatives and pharmaceutically acceptable salts thereof, as well as thrombocyta aggregation inhibiting pharmaceutical compositions comprising such active ingredients | |
| CS241042B2 (cs) | Způsob výroby derivátů 2-be.nzyl-l,2-dihydro-l-oxoftalazin-4-yloctové kyseliny - |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: IMPERIAL CHEMICAL INDUSTRIES LTD |